TP53 and cancer: Conceptually, we further speculate that in cancer cells carrying gain-of-function p53 mutants, CuET could have dual anti-cancer activity, captivating mutant p53 in NPL4-rich aggregates while in parallel imposing its p53-independent cytotoxic program.